ERK1 Antibody (YA5531)

ERK1 (MAPK3) is a serine/threonine protein kinase that functions as an essential effector of the MAPK/ERK signaling cascade and transduces extracellular signals controlling cell proliferation, differentiation, migration, and survival^[1][2]. Mechanistically, ERK1 operates downstream of the Ras/Raf/MEK pathway, where dual phosphorylation activates ERK signaling and enables phosphorylation of numerous substrates across multiple cellular compartments, thereby regulating gene expression and diverse physiological processes^[2]. Because the MAPK/ERK pathway integrates growth factor, hormone, and stress-associated signals, dysregulated ERK signaling contributes to pathological conditions including cancer and other diseases characterized by aberrant cellular proliferation and survival signaling^[1]. In experimental systems, ERK1 has been extensively investigated in developmental, vascular, and disease models to define its contribution to signal transduction and tissue responses^[2][3]. Compared with the closely related isoform ERK2 (MAPK1), ERK1 exhibits highly conserved activation mechanisms, substrate recognition properties, and signaling outputs, and current evidence generally supports substantial functional redundancy between the two kinases^[2]. Nevertheless, isoform-specific studies have identified distinct biological contexts in which ERK1 and ERK2 contribute differently to physiological processes, including vascular remodeling and arteriogenesis, indicating that isoform-dependent functions can emerge in specific cellular environments^[3]. For experimental applications, pharmacological ERK1/2 inhibitors are widely used to interrogate terminal MAPK pathway signaling and to investigate mechanisms of therapeutic resistance associated with reactivation of ERK signaling downstream of RAF or MEK inhibition^[1].